Medarex, Cell Genesys start trial of combo cancer drugs

09/14/2004 | Forbes · MarketWatch

News the two companies were beginning tests on their drugs as a combination therapy for prostate cancer drove their stock values up more than 5%. The multidose, dose-escalation trial is on Medarex's antibody treatment MDX-010, thought to help shrink some tumors, combined with Cell Genesys' investigative cancer vaccine GVAX, and involves up to 45 patients with advanced prostate tumors. Researchers are looking for safety factors and a maximum-tolerated dose level.

View Full Article in:

Forbes · MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN